nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—SLCO1B3—Docetaxel—pancreatic cancer	0.109	0.145	CbGbCtD
Atazanavir—ABCC1—Epirubicin—pancreatic cancer	0.106	0.141	CbGbCtD
Atazanavir—ABCC1—Irinotecan—pancreatic cancer	0.103	0.137	CbGbCtD
Atazanavir—ABCC1—Docetaxel—pancreatic cancer	0.0754	0.101	CbGbCtD
Atazanavir—ABCC1—Doxorubicin—pancreatic cancer	0.0562	0.075	CbGbCtD
Atazanavir—CYP2C9—Tamoxifen—pancreatic cancer	0.0333	0.0444	CbGbCtD
Atazanavir—ABCB1—Tamoxifen—pancreatic cancer	0.0323	0.0431	CbGbCtD
Atazanavir—ABCB1—Gemcitabine—pancreatic cancer	0.0279	0.0371	CbGbCtD
Atazanavir—ABCB1—Erlotinib—pancreatic cancer	0.0275	0.0367	CbGbCtD
Atazanavir—ABCB1—Irinotecan—pancreatic cancer	0.0248	0.0331	CbGbCtD
Atazanavir—CYP2C9—Fluorouracil—pancreatic cancer	0.0246	0.0327	CbGbCtD
Atazanavir—CYP3A4—Tamoxifen—pancreatic cancer	0.0194	0.0258	CbGbCtD
Atazanavir—ABCB1—Docetaxel—pancreatic cancer	0.0182	0.0243	CbGbCtD
Atazanavir—ABCB1—Sunitinib—pancreatic cancer	0.0181	0.0242	CbGbCtD
Atazanavir—CYP3A4—Erlotinib—pancreatic cancer	0.0165	0.022	CbGbCtD
Atazanavir—CYP3A4—Irinotecan—pancreatic cancer	0.0149	0.0198	CbGbCtD
Atazanavir—ABCB1—Doxorubicin—pancreatic cancer	0.0136	0.0181	CbGbCtD
Atazanavir—CYP3A4—Docetaxel—pancreatic cancer	0.0109	0.0145	CbGbCtD
Atazanavir—CYP3A4—Sunitinib—pancreatic cancer	0.0109	0.0145	CbGbCtD
Atazanavir—CYP3A4—Doxorubicin—pancreatic cancer	0.00813	0.0108	CbGbCtD
Atazanavir—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000159	0.000635	CcSEcCtD
Atazanavir—Vomiting—Sunitinib—pancreatic cancer	0.000158	0.000633	CcSEcCtD
Atazanavir—Body temperature increased—Gemcitabine—pancreatic cancer	0.000158	0.000632	CcSEcCtD
Atazanavir—Neutropenia—Epirubicin—pancreatic cancer	0.000157	0.000629	CcSEcCtD
Atazanavir—Rash—Sunitinib—pancreatic cancer	0.000157	0.000628	CcSEcCtD
Atazanavir—Dermatitis—Sunitinib—pancreatic cancer	0.000157	0.000627	CcSEcCtD
Atazanavir—Abdominal distension—Doxorubicin—pancreatic cancer	0.000157	0.000626	CcSEcCtD
Atazanavir—Urticaria—Fluorouracil—pancreatic cancer	0.000156	0.000624	CcSEcCtD
Atazanavir—Headache—Sunitinib—pancreatic cancer	0.000156	0.000624	CcSEcCtD
Atazanavir—Syncope—Docetaxel—pancreatic cancer	0.000156	0.000623	CcSEcCtD
Atazanavir—Pollakiuria—Epirubicin—pancreatic cancer	0.000155	0.000621	CcSEcCtD
Atazanavir—Body temperature increased—Fluorouracil—pancreatic cancer	0.000155	0.000621	CcSEcCtD
Atazanavir—Eosinophilia—Doxorubicin—pancreatic cancer	0.000154	0.000616	CcSEcCtD
Atazanavir—Palpitations—Docetaxel—pancreatic cancer	0.000153	0.000614	CcSEcCtD
Atazanavir—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000153	0.000614	CcSEcCtD
Atazanavir—Weight increased—Epirubicin—pancreatic cancer	0.000153	0.000612	CcSEcCtD
Atazanavir—Loss of consciousness—Docetaxel—pancreatic cancer	0.000153	0.000611	CcSEcCtD
Atazanavir—Pancreatitis—Doxorubicin—pancreatic cancer	0.000152	0.00061	CcSEcCtD
Atazanavir—Weight decreased—Epirubicin—pancreatic cancer	0.000152	0.000608	CcSEcCtD
Atazanavir—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000152	0.000607	CcSEcCtD
Atazanavir—Cough—Docetaxel—pancreatic cancer	0.000151	0.000606	CcSEcCtD
Atazanavir—Hypersensitivity—Irinotecan—pancreatic cancer	0.000151	0.000604	CcSEcCtD
Atazanavir—Convulsion—Docetaxel—pancreatic cancer	0.00015	0.000602	CcSEcCtD
Atazanavir—Hypertension—Docetaxel—pancreatic cancer	0.00015	0.0006	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000149	0.000595	CcSEcCtD
Atazanavir—Myalgia—Docetaxel—pancreatic cancer	0.000148	0.000591	CcSEcCtD
Atazanavir—Chest pain—Docetaxel—pancreatic cancer	0.000148	0.000591	CcSEcCtD
Atazanavir—Arthralgia—Docetaxel—pancreatic cancer	0.000148	0.000591	CcSEcCtD
Atazanavir—Nausea—Sunitinib—pancreatic cancer	0.000148	0.000591	CcSEcCtD
Atazanavir—Renal failure—Epirubicin—pancreatic cancer	0.000147	0.000589	CcSEcCtD
Atazanavir—Asthenia—Irinotecan—pancreatic cancer	0.000147	0.000589	CcSEcCtD
Atazanavir—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000147	0.000588	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000147	0.000587	CcSEcCtD
Atazanavir—Jaundice—Epirubicin—pancreatic cancer	0.000146	0.000585	CcSEcCtD
Atazanavir—Stomatitis—Epirubicin—pancreatic cancer	0.000146	0.000585	CcSEcCtD
Atazanavir—Urinary tract infection—Epirubicin—pancreatic cancer	0.000146	0.000583	CcSEcCtD
Atazanavir—Neutropenia—Doxorubicin—pancreatic cancer	0.000145	0.000582	CcSEcCtD
Atazanavir—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000145	0.000579	CcSEcCtD
Atazanavir—Dry mouth—Docetaxel—pancreatic cancer	0.000145	0.000578	CcSEcCtD
Atazanavir—Sweating—Epirubicin—pancreatic cancer	0.000144	0.000575	CcSEcCtD
Atazanavir—Pollakiuria—Doxorubicin—pancreatic cancer	0.000144	0.000575	CcSEcCtD
Atazanavir—Asthenia—Gemcitabine—pancreatic cancer	0.000143	0.000573	CcSEcCtD
Atazanavir—Haematuria—Epirubicin—pancreatic cancer	0.000143	0.000572	CcSEcCtD
Atazanavir—Confusional state—Docetaxel—pancreatic cancer	0.000143	0.000572	CcSEcCtD
Atazanavir—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000142	0.000568	CcSEcCtD
Atazanavir—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000142	0.000567	CcSEcCtD
Atazanavir—Oedema—Docetaxel—pancreatic cancer	0.000142	0.000567	CcSEcCtD
Atazanavir—Weight increased—Doxorubicin—pancreatic cancer	0.000141	0.000566	CcSEcCtD
Atazanavir—Pruritus—Gemcitabine—pancreatic cancer	0.000141	0.000565	CcSEcCtD
Atazanavir—Infection—Docetaxel—pancreatic cancer	0.000141	0.000563	CcSEcCtD
Atazanavir—Weight decreased—Doxorubicin—pancreatic cancer	0.000141	0.000563	CcSEcCtD
Atazanavir—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.00014	0.000561	CcSEcCtD
Atazanavir—Diarrhoea—Irinotecan—pancreatic cancer	0.00014	0.000561	CcSEcCtD
Atazanavir—Shock—Docetaxel—pancreatic cancer	0.000139	0.000558	CcSEcCtD
Atazanavir—Nervous system disorder—Docetaxel—pancreatic cancer	0.000139	0.000556	CcSEcCtD
Atazanavir—Pruritus—Fluorouracil—pancreatic cancer	0.000139	0.000556	CcSEcCtD
Atazanavir—Skin disorder—Docetaxel—pancreatic cancer	0.000138	0.000551	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000137	0.00055	CcSEcCtD
Atazanavir—Diarrhoea—Gemcitabine—pancreatic cancer	0.000137	0.000547	CcSEcCtD
Atazanavir—Renal failure—Doxorubicin—pancreatic cancer	0.000136	0.000545	CcSEcCtD
Atazanavir—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000136	0.000544	CcSEcCtD
Atazanavir—Dizziness—Irinotecan—pancreatic cancer	0.000136	0.000542	CcSEcCtD
Atazanavir—Stomatitis—Doxorubicin—pancreatic cancer	0.000135	0.000541	CcSEcCtD
Atazanavir—Jaundice—Doxorubicin—pancreatic cancer	0.000135	0.000541	CcSEcCtD
Atazanavir—Anorexia—Docetaxel—pancreatic cancer	0.000135	0.00054	CcSEcCtD
Atazanavir—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000135	0.000539	CcSEcCtD
Atazanavir—Hepatitis—Epirubicin—pancreatic cancer	0.000135	0.000538	CcSEcCtD
Atazanavir—Diarrhoea—Fluorouracil—pancreatic cancer	0.000134	0.000538	CcSEcCtD
Atazanavir—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000134	0.000536	CcSEcCtD
Atazanavir—Sweating—Doxorubicin—pancreatic cancer	0.000133	0.000532	CcSEcCtD
Atazanavir—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000133	0.000532	CcSEcCtD
Atazanavir—Oedema peripheral—Epirubicin—pancreatic cancer	0.000132	0.00053	CcSEcCtD
Atazanavir—Haematuria—Doxorubicin—pancreatic cancer	0.000132	0.000529	CcSEcCtD
Atazanavir—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000132	0.000529	CcSEcCtD
Atazanavir—Urethral disorder—Epirubicin—pancreatic cancer	0.000132	0.000528	CcSEcCtD
Atazanavir—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000131	0.000525	CcSEcCtD
Atazanavir—Vomiting—Irinotecan—pancreatic cancer	0.00013	0.000522	CcSEcCtD
Atazanavir—Dizziness—Fluorouracil—pancreatic cancer	0.00013	0.00052	CcSEcCtD
Atazanavir—Rash—Irinotecan—pancreatic cancer	0.000129	0.000517	CcSEcCtD
Atazanavir—Dermatitis—Irinotecan—pancreatic cancer	0.000129	0.000517	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000129	0.000517	CcSEcCtD
Atazanavir—Headache—Irinotecan—pancreatic cancer	0.000128	0.000514	CcSEcCtD
Atazanavir—Insomnia—Docetaxel—pancreatic cancer	0.000128	0.000513	CcSEcCtD
Atazanavir—Erythema multiforme—Epirubicin—pancreatic cancer	0.000127	0.000509	CcSEcCtD
Atazanavir—Vomiting—Gemcitabine—pancreatic cancer	0.000127	0.000508	CcSEcCtD
Atazanavir—Dyspnoea—Docetaxel—pancreatic cancer	0.000126	0.000506	CcSEcCtD
Atazanavir—Somnolence—Docetaxel—pancreatic cancer	0.000126	0.000504	CcSEcCtD
Atazanavir—Rash—Gemcitabine—pancreatic cancer	0.000126	0.000504	CcSEcCtD
Atazanavir—Dermatitis—Gemcitabine—pancreatic cancer	0.000126	0.000503	CcSEcCtD
Atazanavir—Eye disorder—Epirubicin—pancreatic cancer	0.000126	0.000503	CcSEcCtD
Atazanavir—Tinnitus—Epirubicin—pancreatic cancer	0.000125	0.000502	CcSEcCtD
Atazanavir—Headache—Gemcitabine—pancreatic cancer	0.000125	0.000501	CcSEcCtD
Atazanavir—Cardiac disorder—Epirubicin—pancreatic cancer	0.000125	0.0005	CcSEcCtD
Atazanavir—Vomiting—Fluorouracil—pancreatic cancer	0.000125	0.000499	CcSEcCtD
Atazanavir—Dyspepsia—Docetaxel—pancreatic cancer	0.000125	0.000499	CcSEcCtD
Atazanavir—Hepatitis—Doxorubicin—pancreatic cancer	0.000124	0.000498	CcSEcCtD
Atazanavir—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000124	0.000496	CcSEcCtD
Atazanavir—Rash—Fluorouracil—pancreatic cancer	0.000124	0.000495	CcSEcCtD
Atazanavir—Dermatitis—Fluorouracil—pancreatic cancer	0.000124	0.000495	CcSEcCtD
Atazanavir—Decreased appetite—Docetaxel—pancreatic cancer	0.000123	0.000493	CcSEcCtD
Atazanavir—Headache—Fluorouracil—pancreatic cancer	0.000123	0.000492	CcSEcCtD
Atazanavir—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000123	0.000492	CcSEcCtD
Atazanavir—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000123	0.000491	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000122	0.00049	CcSEcCtD
Atazanavir—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000122	0.000489	CcSEcCtD
Atazanavir—Fatigue—Docetaxel—pancreatic cancer	0.000122	0.000489	CcSEcCtD
Atazanavir—Angiopathy—Epirubicin—pancreatic cancer	0.000122	0.000488	CcSEcCtD
Atazanavir—Urethral disorder—Doxorubicin—pancreatic cancer	0.000122	0.000488	CcSEcCtD
Atazanavir—Nausea—Irinotecan—pancreatic cancer	0.000122	0.000487	CcSEcCtD
Atazanavir—Immune system disorder—Epirubicin—pancreatic cancer	0.000121	0.000486	CcSEcCtD
Atazanavir—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000121	0.000485	CcSEcCtD
Atazanavir—Pain—Docetaxel—pancreatic cancer	0.000121	0.000485	CcSEcCtD
Atazanavir—Constipation—Docetaxel—pancreatic cancer	0.000121	0.000485	CcSEcCtD
Atazanavir—Alopecia—Epirubicin—pancreatic cancer	0.000119	0.000476	CcSEcCtD
Atazanavir—Nausea—Gemcitabine—pancreatic cancer	0.000119	0.000475	CcSEcCtD
Atazanavir—Mental disorder—Epirubicin—pancreatic cancer	0.000118	0.000472	CcSEcCtD
Atazanavir—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000118	0.000471	CcSEcCtD
Atazanavir—Malnutrition—Epirubicin—pancreatic cancer	0.000117	0.000469	CcSEcCtD
Atazanavir—Feeling abnormal—Docetaxel—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Atazanavir—Nausea—Fluorouracil—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Atazanavir—Eye disorder—Doxorubicin—pancreatic cancer	0.000116	0.000465	CcSEcCtD
Atazanavir—Tinnitus—Doxorubicin—pancreatic cancer	0.000116	0.000464	CcSEcCtD
Atazanavir—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000116	0.000464	CcSEcCtD
Atazanavir—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000115	0.000462	CcSEcCtD
Atazanavir—Flatulence—Epirubicin—pancreatic cancer	0.000115	0.000462	CcSEcCtD
Atazanavir—Tension—Epirubicin—pancreatic cancer	0.000115	0.00046	CcSEcCtD
Atazanavir—Dysgeusia—Epirubicin—pancreatic cancer	0.000115	0.000459	CcSEcCtD
Atazanavir—Nervousness—Epirubicin—pancreatic cancer	0.000114	0.000455	CcSEcCtD
Atazanavir—Back pain—Epirubicin—pancreatic cancer	0.000113	0.000453	CcSEcCtD
Atazanavir—Angiopathy—Doxorubicin—pancreatic cancer	0.000113	0.000452	CcSEcCtD
Atazanavir—Immune system disorder—Doxorubicin—pancreatic cancer	0.000112	0.00045	CcSEcCtD
Atazanavir—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000112	0.000449	CcSEcCtD
Atazanavir—Abdominal pain—Docetaxel—pancreatic cancer	0.000112	0.000448	CcSEcCtD
Atazanavir—Body temperature increased—Docetaxel—pancreatic cancer	0.000112	0.000448	CcSEcCtD
Atazanavir—Alopecia—Doxorubicin—pancreatic cancer	0.00011	0.00044	CcSEcCtD
Atazanavir—Mental disorder—Doxorubicin—pancreatic cancer	0.000109	0.000436	CcSEcCtD
Atazanavir—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000109	0.000435	CcSEcCtD
Atazanavir—Malnutrition—Doxorubicin—pancreatic cancer	0.000108	0.000434	CcSEcCtD
Atazanavir—Agitation—Epirubicin—pancreatic cancer	0.000108	0.000431	CcSEcCtD
Atazanavir—Flatulence—Doxorubicin—pancreatic cancer	0.000107	0.000427	CcSEcCtD
Atazanavir—Tension—Doxorubicin—pancreatic cancer	0.000106	0.000425	CcSEcCtD
Atazanavir—Dysgeusia—Doxorubicin—pancreatic cancer	0.000106	0.000425	CcSEcCtD
Atazanavir—Malaise—Epirubicin—pancreatic cancer	0.000106	0.000423	CcSEcCtD
Atazanavir—Nervousness—Doxorubicin—pancreatic cancer	0.000105	0.000421	CcSEcCtD
Atazanavir—Syncope—Epirubicin—pancreatic cancer	0.000105	0.00042	CcSEcCtD
Atazanavir—Back pain—Doxorubicin—pancreatic cancer	0.000105	0.000419	CcSEcCtD
Atazanavir—Hypersensitivity—Docetaxel—pancreatic cancer	0.000104	0.000418	CcSEcCtD
Atazanavir—Palpitations—Epirubicin—pancreatic cancer	0.000103	0.000414	CcSEcCtD
Atazanavir—Loss of consciousness—Epirubicin—pancreatic cancer	0.000103	0.000412	CcSEcCtD
Atazanavir—Cough—Epirubicin—pancreatic cancer	0.000102	0.000409	CcSEcCtD
Atazanavir—Asthenia—Docetaxel—pancreatic cancer	0.000102	0.000407	CcSEcCtD
Atazanavir—Convulsion—Epirubicin—pancreatic cancer	0.000101	0.000406	CcSEcCtD
Atazanavir—Hypertension—Epirubicin—pancreatic cancer	0.000101	0.000405	CcSEcCtD
Atazanavir—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000101	0.000402	CcSEcCtD
Atazanavir—Pruritus—Docetaxel—pancreatic cancer	0.0001	0.000401	CcSEcCtD
Atazanavir—Arthralgia—Epirubicin—pancreatic cancer	9.97e-05	0.000399	CcSEcCtD
Atazanavir—Chest pain—Epirubicin—pancreatic cancer	9.97e-05	0.000399	CcSEcCtD
Atazanavir—Myalgia—Epirubicin—pancreatic cancer	9.97e-05	0.000399	CcSEcCtD
Atazanavir—Agitation—Doxorubicin—pancreatic cancer	9.96e-05	0.000398	CcSEcCtD
Atazanavir—Anxiety—Epirubicin—pancreatic cancer	9.93e-05	0.000398	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	9.9e-05	0.000396	CcSEcCtD
Atazanavir—Discomfort—Epirubicin—pancreatic cancer	9.85e-05	0.000394	CcSEcCtD
Atazanavir—Malaise—Doxorubicin—pancreatic cancer	9.77e-05	0.000391	CcSEcCtD
Atazanavir—Dry mouth—Epirubicin—pancreatic cancer	9.75e-05	0.00039	CcSEcCtD
Atazanavir—Syncope—Doxorubicin—pancreatic cancer	9.72e-05	0.000389	CcSEcCtD
Atazanavir—Diarrhoea—Docetaxel—pancreatic cancer	9.69e-05	0.000388	CcSEcCtD
Atazanavir—Confusional state—Epirubicin—pancreatic cancer	9.64e-05	0.000386	CcSEcCtD
Atazanavir—Palpitations—Doxorubicin—pancreatic cancer	9.57e-05	0.000383	CcSEcCtD
Atazanavir—Oedema—Epirubicin—pancreatic cancer	9.56e-05	0.000382	CcSEcCtD
Atazanavir—Loss of consciousness—Doxorubicin—pancreatic cancer	9.52e-05	0.000381	CcSEcCtD
Atazanavir—Infection—Epirubicin—pancreatic cancer	9.49e-05	0.00038	CcSEcCtD
Atazanavir—Cough—Doxorubicin—pancreatic cancer	9.45e-05	0.000378	CcSEcCtD
Atazanavir—Shock—Epirubicin—pancreatic cancer	9.4e-05	0.000376	CcSEcCtD
Atazanavir—Convulsion—Doxorubicin—pancreatic cancer	9.39e-05	0.000376	CcSEcCtD
Atazanavir—Nervous system disorder—Epirubicin—pancreatic cancer	9.37e-05	0.000375	CcSEcCtD
Atazanavir—Dizziness—Docetaxel—pancreatic cancer	9.37e-05	0.000375	CcSEcCtD
Atazanavir—Hypertension—Doxorubicin—pancreatic cancer	9.35e-05	0.000374	CcSEcCtD
Atazanavir—Skin disorder—Epirubicin—pancreatic cancer	9.28e-05	0.000371	CcSEcCtD
Atazanavir—Hyperhidrosis—Epirubicin—pancreatic cancer	9.24e-05	0.00037	CcSEcCtD
Atazanavir—Myalgia—Doxorubicin—pancreatic cancer	9.22e-05	0.000369	CcSEcCtD
Atazanavir—Chest pain—Doxorubicin—pancreatic cancer	9.22e-05	0.000369	CcSEcCtD
Atazanavir—Arthralgia—Doxorubicin—pancreatic cancer	9.22e-05	0.000369	CcSEcCtD
Atazanavir—Anxiety—Doxorubicin—pancreatic cancer	9.19e-05	0.000368	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	9.16e-05	0.000367	CcSEcCtD
Atazanavir—Discomfort—Doxorubicin—pancreatic cancer	9.11e-05	0.000365	CcSEcCtD
Atazanavir—Anorexia—Epirubicin—pancreatic cancer	9.11e-05	0.000365	CcSEcCtD
Atazanavir—Dry mouth—Doxorubicin—pancreatic cancer	9.02e-05	0.000361	CcSEcCtD
Atazanavir—Vomiting—Docetaxel—pancreatic cancer	9.01e-05	0.000361	CcSEcCtD
Atazanavir—Rash—Docetaxel—pancreatic cancer	8.93e-05	0.000358	CcSEcCtD
Atazanavir—Dermatitis—Docetaxel—pancreatic cancer	8.92e-05	0.000357	CcSEcCtD
Atazanavir—Confusional state—Doxorubicin—pancreatic cancer	8.92e-05	0.000357	CcSEcCtD
Atazanavir—Headache—Docetaxel—pancreatic cancer	8.88e-05	0.000355	CcSEcCtD
Atazanavir—Oedema—Doxorubicin—pancreatic cancer	8.84e-05	0.000354	CcSEcCtD
Atazanavir—Infection—Doxorubicin—pancreatic cancer	8.78e-05	0.000352	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	8.71e-05	0.000348	CcSEcCtD
Atazanavir—Shock—Doxorubicin—pancreatic cancer	8.7e-05	0.000348	CcSEcCtD
Atazanavir—Nervous system disorder—Doxorubicin—pancreatic cancer	8.67e-05	0.000347	CcSEcCtD
Atazanavir—Insomnia—Epirubicin—pancreatic cancer	8.64e-05	0.000346	CcSEcCtD
Atazanavir—Skin disorder—Doxorubicin—pancreatic cancer	8.59e-05	0.000344	CcSEcCtD
Atazanavir—Hyperhidrosis—Doxorubicin—pancreatic cancer	8.55e-05	0.000342	CcSEcCtD
Atazanavir—Dyspnoea—Epirubicin—pancreatic cancer	8.52e-05	0.000341	CcSEcCtD
Atazanavir—Somnolence—Epirubicin—pancreatic cancer	8.5e-05	0.00034	CcSEcCtD
Atazanavir—Anorexia—Doxorubicin—pancreatic cancer	8.43e-05	0.000337	CcSEcCtD
Atazanavir—Nausea—Docetaxel—pancreatic cancer	8.42e-05	0.000337	CcSEcCtD
Atazanavir—Dyspepsia—Epirubicin—pancreatic cancer	8.41e-05	0.000337	CcSEcCtD
Atazanavir—Decreased appetite—Epirubicin—pancreatic cancer	8.31e-05	0.000332	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Epirubicin—pancreatic cancer	8.25e-05	0.00033	CcSEcCtD
Atazanavir—Fatigue—Epirubicin—pancreatic cancer	8.24e-05	0.00033	CcSEcCtD
Atazanavir—Pain—Epirubicin—pancreatic cancer	8.17e-05	0.000327	CcSEcCtD
Atazanavir—Constipation—Epirubicin—pancreatic cancer	8.17e-05	0.000327	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	8.06e-05	0.000322	CcSEcCtD
Atazanavir—Insomnia—Doxorubicin—pancreatic cancer	8e-05	0.00032	CcSEcCtD
Atazanavir—Dyspnoea—Doxorubicin—pancreatic cancer	7.88e-05	0.000315	CcSEcCtD
Atazanavir—Feeling abnormal—Epirubicin—pancreatic cancer	7.87e-05	0.000315	CcSEcCtD
Atazanavir—Somnolence—Doxorubicin—pancreatic cancer	7.86e-05	0.000315	CcSEcCtD
Atazanavir—Gastrointestinal pain—Epirubicin—pancreatic cancer	7.81e-05	0.000313	CcSEcCtD
Atazanavir—Dyspepsia—Doxorubicin—pancreatic cancer	7.78e-05	0.000312	CcSEcCtD
Atazanavir—Decreased appetite—Doxorubicin—pancreatic cancer	7.69e-05	0.000308	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	7.63e-05	0.000306	CcSEcCtD
Atazanavir—Fatigue—Doxorubicin—pancreatic cancer	7.62e-05	0.000305	CcSEcCtD
Atazanavir—Urticaria—Epirubicin—pancreatic cancer	7.59e-05	0.000304	CcSEcCtD
Atazanavir—Pain—Doxorubicin—pancreatic cancer	7.56e-05	0.000303	CcSEcCtD
Atazanavir—Constipation—Doxorubicin—pancreatic cancer	7.56e-05	0.000303	CcSEcCtD
Atazanavir—Body temperature increased—Epirubicin—pancreatic cancer	7.55e-05	0.000302	CcSEcCtD
Atazanavir—Abdominal pain—Epirubicin—pancreatic cancer	7.55e-05	0.000302	CcSEcCtD
Atazanavir—Feeling abnormal—Doxorubicin—pancreatic cancer	7.29e-05	0.000292	CcSEcCtD
Atazanavir—Gastrointestinal pain—Doxorubicin—pancreatic cancer	7.23e-05	0.000289	CcSEcCtD
Atazanavir—Hypersensitivity—Epirubicin—pancreatic cancer	7.04e-05	0.000282	CcSEcCtD
Atazanavir—Urticaria—Doxorubicin—pancreatic cancer	7.02e-05	0.000281	CcSEcCtD
Atazanavir—Body temperature increased—Doxorubicin—pancreatic cancer	6.99e-05	0.00028	CcSEcCtD
Atazanavir—Abdominal pain—Doxorubicin—pancreatic cancer	6.99e-05	0.00028	CcSEcCtD
Atazanavir—Asthenia—Epirubicin—pancreatic cancer	6.86e-05	0.000274	CcSEcCtD
Atazanavir—Pruritus—Epirubicin—pancreatic cancer	6.76e-05	0.000271	CcSEcCtD
Atazanavir—Diarrhoea—Epirubicin—pancreatic cancer	6.54e-05	0.000262	CcSEcCtD
Atazanavir—Hypersensitivity—Doxorubicin—pancreatic cancer	6.51e-05	0.000261	CcSEcCtD
Atazanavir—Asthenia—Doxorubicin—pancreatic cancer	6.34e-05	0.000254	CcSEcCtD
Atazanavir—Dizziness—Epirubicin—pancreatic cancer	6.32e-05	0.000253	CcSEcCtD
Atazanavir—Pruritus—Doxorubicin—pancreatic cancer	6.26e-05	0.00025	CcSEcCtD
Atazanavir—Vomiting—Epirubicin—pancreatic cancer	6.08e-05	0.000243	CcSEcCtD
Atazanavir—Diarrhoea—Doxorubicin—pancreatic cancer	6.05e-05	0.000242	CcSEcCtD
Atazanavir—Rash—Epirubicin—pancreatic cancer	6.03e-05	0.000241	CcSEcCtD
Atazanavir—Dermatitis—Epirubicin—pancreatic cancer	6.02e-05	0.000241	CcSEcCtD
Atazanavir—Headache—Epirubicin—pancreatic cancer	5.99e-05	0.00024	CcSEcCtD
Atazanavir—Dizziness—Doxorubicin—pancreatic cancer	5.85e-05	0.000234	CcSEcCtD
Atazanavir—Nausea—Epirubicin—pancreatic cancer	5.68e-05	0.000227	CcSEcCtD
Atazanavir—Vomiting—Doxorubicin—pancreatic cancer	5.62e-05	0.000225	CcSEcCtD
Atazanavir—Rash—Doxorubicin—pancreatic cancer	5.57e-05	0.000223	CcSEcCtD
Atazanavir—Dermatitis—Doxorubicin—pancreatic cancer	5.57e-05	0.000223	CcSEcCtD
Atazanavir—Headache—Doxorubicin—pancreatic cancer	5.54e-05	0.000222	CcSEcCtD
Atazanavir—Nausea—Doxorubicin—pancreatic cancer	5.25e-05	0.00021	CcSEcCtD
